Zoetis Inc. $ZTS Position Increased by Confluence Investment Management LLC

Confluence Investment Management LLC grew its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 228.1% during the second quarter, Holdings Channel reports. The firm owned 465,449 shares of the company’s stock after acquiring an additional 323,586 shares during the quarter. Confluence Investment Management LLC’s holdings in Zoetis were worth $33,447,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. RFG Advisory LLC grew its position in shares of Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the last quarter. Quest 10 Wealth Builders Inc. boosted its stake in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares during the period. Financial Engines Advisors L.L.C. grew its holdings in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after purchasing an additional 87 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych grew its holdings in shares of Zoetis by 20.9% during the fourth quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 520 shares of the company’s stock valued at $65,000 after purchasing an additional 90 shares during the last quarter. Finally, Physician Wealth Advisors Inc. raised its position in shares of Zoetis by 17.4% during the 1st quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after purchasing an additional 91 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $77.13 on Tuesday. Zoetis Inc. has a 12-month low of $71.47 and a 12-month high of $160.48. The company has a market cap of $32.33 billion, a PE ratio of 12.79, a P/E/G ratio of 1.21 and a beta of 0.73. The stock has a 50 day simple moving average of $76.97 and a 200-day simple moving average of $101.99. The company has a current ratio of 3.15, a quick ratio of 1.91 and a debt-to-equity ratio of 2.80.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is 35.16%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Barclays cut their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. TD Cowen cut their target price on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. HSBC reduced their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Morgan Stanley dropped their price objective on shares of Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $118.33.

Insider Activity at Zoetis

In related news, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the transaction, the director directly owned 24,524 shares of the company’s stock, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This trade represents a 7.73% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last ninety days. 0.22% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.